Addex Therapeutics (NASDAQ:ADXN) Rating Reiterated by HC Wainwright

Addex Therapeutics (NASDAQ:ADXN)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They currently have a $30.00 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 193.26% from the company’s previous close. HC Wainwright also issued estimates for Addex Therapeutics’ Q1 2025 earnings at ($0.21) EPS, Q2 2025 earnings at ($0.07) EPS, Q3 2025 earnings at ($0.07) EPS and Q4 2025 earnings at ($0.07) EPS.

Addex Therapeutics Stock Performance

ADXN stock opened at $10.23 on Wednesday. The firm has a market cap of $10.84 million, a P/E ratio of -0.59 and a beta of 1.77. The stock’s 50 day moving average price is $8.15 and its 200 day moving average price is $10.60. Addex Therapeutics has a 1 year low of $5.00 and a 1 year high of $27.90.

Addex Therapeutics (NASDAQ:ADXN) last issued its quarterly earnings results on Thursday, June 6th. The company reported ($1.37) EPS for the quarter. The firm had revenue of $0.27 million for the quarter. Addex Therapeutics had a negative return on equity of 364.24% and a negative net margin of 818.50%. On average, research analysts predict that Addex Therapeutics will post -11.8 earnings per share for the current year.

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.